IL6 and infection: Tocilizumab (TCZ), as a representative antagonist of IL-6, has been used to treat RA; however, its serious adverse side effect is that infectious disease related to C-reactive protein (CRP) cannot be recognized during TCZ treatment [46]; this implies that stealth infections without any specific signals can wreak havoc on patients’ condition.